Abbott, Celera Dx's PCR-Based Hepatitis B Assay Wins CE Mark | GenomeWeb
NEW YORK (GenomeWeb News) — European Union regulators have cleared an Abbott assay that uses real-time PCR to monitor hepatitis B viral loads, Abbott and partner Celera Diagnostics said yesterday.
 
The certification allows the companies to market the test in the EU. The test runs on Abbott’s m2000 instrument, which uses PCR technology made by Applied Biosystems.
 
The m2000 also runs PCR tests for HIV-1, hepatitis C, chlamydia, and a combination test for chlamydia or gonorrhea.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.